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Summary
Objective: To determine in articular cartilage whether degraded type II collagen is more abundant in Col11a1 mutant cho/+ than in
age-matched +/+ mice and whether collagen degradation occurs in a generalized or localized fashion.
Design: Knee joints from cho/+ and +/+ mice at 6, 9, 12 and 15 months of age were dissected, fixed, cryosectioned, and stained with antibody
COL2-3/4m against denatured type II collagen using a FITC-conjugated secondary antibody. Sections were viewed and photographed under
a fluorescence microscope and areas of staining were quantified.
Results: Before 12 months of age, little degraded collagen staining was detectable in +/+ or cho/+ mice. By 15 months, however, cho/+ mice
showed significantly more degraded type II collagen than age-matched controls. Degraded collagen staining was localized at the articular
surface, not distributed generally throughout the articular cartilage.
Conclusions: The results suggest a model in which cumulative biomechanical stresses trigger increased collagen synthesis and degradation
in both +/+ and cho/+ mice at around 12 months of age. Cho/+ mice, however, are less able to synthesize and assemble normal replacement
collagen fibrils because of the Col11a1 mutation. Degradation is further activated, resulting in the accumulation of degraded type II collagen
in the articular cartilage extracellular matrix. Similar mutations that do not overtly affect skeletal development may likewise predispose
humans to increased collagen degradation and resultant osteoarthritis.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Normal articular cartilage can withstand enormous com-
pressive forces and provides an almost frictionless surface
for joint movement. Cartilage abnormalities, however, can
cause the progressive degeneration of the articular
surface, a condition known as osteoarthritis (OA). Such
degeneration causes pain and decreased range of motion
in the affected joints. Mutations in several different cartilage
collagen genes, including Col2a1, Col11a1, Col11a2,
Col9a1, and Col9a3, have been linked to chondrodysplasia
and premature OA in humans1–8. It is likely that mutations
in other genes coding for components of the cartilage
extracellular matrix are also capable of predisposing an
individual to OA by compromising the structural integrity of
the articular cartilage. For this reason, research animals
carrying mutations in components of the cartilage extra-
cellular matrix are of particular interest as possible models
of OA.
Mice that are homozygous for the mutation chondro-
dysplasia (cho) die at birth with severe skeletal abnormali-
ties affecting the rib cage, limb length, trunk length,
mandible, palate, and trachea9–12. Mice that are hetero-
zygous for the mutation, on the other hand, appear pheno-
typically normal. In 1995 the cho mutation was shown to be
a 1-bp deletion in the type XI collagen gene, Col11a1,
which produces a premature stop codon and is functionally
equivalent to a knockout of the gene13.
Type XI collagen normally interacts with type II and type
IX collagen to form the meshwork of collagen fibrils that
gives cartilage its unique tensile strength. Mice homo-
zygous for the cho mutation contain abnormally thick
collagen fibrils, suggesting that type XI collagen functions
to limit the diameter of cartilage collagen fibrils in the
extracellular meshwork9. Abnormally thick collagen fibrils
are also found in mice that overexpress type II collagen,
further suggesting that the ratio of type XI to type II collagen
regulates diameter, and that the diameter increases as the
ratio decreases14,15.
The cho mutation is considered recessive because
heterozygous animals survive normally beyond birth and
show no obvious signs of skeletal dysplasia. Our recent
work, however, has suggested that heterozygous cho/+
mice are predisposed to develop early-onset OA. This OA
is manifest histologically as acellular lesions, cell cluster-
ing, and surface erosions in the articular cartilage16.
Recent studies in animal models and human osteo-
arthritic cartilage suggest that increased degradation of
type II collagen is also typical of OA17–24. Type II collagen
can be degraded by at least three different matrix metallo-
proteinases (MMPs), viz., MMP-1, MMP-8, and MMP-13
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(also known as collagenase-1, collagenase-2, and
collagenase-3)20,24. The collagenases digest type II colla-
gen at a unique site, leaving a three-quarter length
N-terminal fragment and a one-quarter length C-terminal
fragment20. The collagen triple helix in these fragments
denatures (unwinds) following cleavage of the molecule.
Type II collagen can also be degraded and denatured by
other, less specific proteases as well as by biomechanical
forces. Denaturation of the type II collagen triple helix
exposes an epitope that is recognized specifically by a
monoclonal antibody called COL2-3/4m25.
The COL2-3/4m antibody has been used to detect type II
collagen degradation in murine models of OA. Collagen
denaturation was found to be localized at sites of cartilage
degeneration in two mouse strains that develop spon-
taneous OA, but was not found in intact articular carti-
lage17. In two induced models of murine OA, collagen
denaturation increased after OA induction in both reversible
and irreversible models of OA18. Furthermore, a transgenic
mouse line that over expresses MMP-13 in cartilage dem-
onstrated a correlation between increased levels of MMP-
13, increased accumulation of degraded type II collagen,
and regions of cartilage degeneration26. These studies and
several others suggest that increased collagenase activity
in articular cartilage may destroy type II collagen faster
than it can be replaced, thus compromising the structural
integrity of the articular cartilage and leading to OA.
The purpose of the present study was to use the COL2-
3/4m antibody to determine whether denatured type II
collagen is detectable at increased levels in articular carti-
lage from heterozygous cho/+ mice. This work has demon-
strated that increased type II collagen degradation occurs
in cartilage from cho/+ mice, and that the difference in
degradation between cho/+ and +/+ mice becomes statisti-
cally significant by 15 months of age. The degradation is
not generalized, but rather occurs first in the superficial
zone and then extends into deeper zones in localized
regions. Areas of deeper staining often corresponded with
regions of roughness and irregularity at the articular sur-
face. These results lend support to the hypothesis that
degradation of type II collagen plays a key role in the
degeneration of articular cartilage in OA. They also dem-
onstrate that a type XI collagen mutation can lead to
increased type II collagen degradation. These results
further establish the cho/+ mouse as a useful model for the
study of OA.
Materials and methods
ANIMALS
Knee joints from 6-, 9-, 12-, and 15-month-old C57BL
mice were used in this study. Genomic DNA was obtained
from tail snips and used to determine the genotype of each
animal, classifying each as cho/+ (experimental group) or
+/+ (control group)13. A total of 17 cho/+ and 17 +/+ mice
were examined – three animals of each genotype at 6
months, three animals of each genotype at 9 months, six
animals of each genotype at 12 months, and five animals of
each genotype at 15 months. Animals were anesthetized
with ether and killed by cervical dislocation as approved by
the Institutional Animal Care and Use Committee of
Brigham Young University. Right knee joints were excised
to mid-femur and mid-tibia and the muscles were dissected
away.
TISSUE PREPARATION
Knee joints were fixed in 4% formaldehyde (freshly
prepared from paraformaldehyde) for 12 h at 4°C. Joints
were then decalcified in Immunocal formic acid decalcifier
(Decal Corporation, Tallman, New York) overnight, frozen
in Tissue-Tek® O.C.T. Compound embedding media
(American Master Tech Scientific Inc., Lodi, California) and
stored for up to five days at −20°C before being sectioned.
Coronal 6-µm thick sections of whole knee joints were
cut at −21°C on a Microm HM 505E cryostat (Zeiss,
Thornwood, New York), mounted on Fisher Superfrost®/
Plus pretreated slides, and stored at −20°C.
The tissue depth targeted for immunohistochemical
staining was between 750 µm and 900 µm beyond the
posterior side of the patella. The Microm HM 505 E cryostat
measured tissue depth as knee joints were sectioned,
facilitating the identification of sections that were within
the pre-determined optimal depth. One section from the
targeted depth in each animal was chosen for staining.
IMMUNOHISTOCHEMISTRY
To enhance the permeability of the extracellular matrix
(ECM), the sections were incubated in hyaluronidase (type
I-S, EC 3.2.1.35; Sigma) 2000 U/ml in PBS pH 5.0 for one
hour at 37°C. Nonspecific staining was blocked with 10%
normal goat serum in PBS with 1% bovine serum albumin
(BSA) (Sigma). In addition, sections were pre-incubated
with unlabeled horse anti-mouse IgGs in order to suppress
the non-specific binding of the goat anti-mouse IgG1 sec-
ondary antibody to endogenous mouse IgG1 binding sites.
Sections were incubated overnight with primary antibody
against denatured type II collagen, the COL2-3/4 m mono-
clonal antibody. This antibody was a kind gift of Dr A. Robin
Poole of the Joint Diseases Laboratory, Shriners Hospital
for Children, in Montreal, Canada. The primary antibody
was diluted at a ratio of 1:500 in PBS with 1% BSA. In order
to detect the primary antibody, sections were washed with
0.1% BSA in PBS then incubated at room temperature with
FITC-conjugated goat anti-mouse secondary antibody.
In order to verify the specificity of the COL2-3/4m mono-
clonal antibody, a 1:200 dilution of the antibody was pre-
coupled with 100 µg/ml of its 13 amino acid epitope
peptide, CB11B, for one hour at 37°C and then used to
stain tissue sections. Adjacent sections were stained with
the same antibody not pre-coupled with the peptide. The
sections incubated with the pre-coupled antibody–peptide
complex did not show staining in the articular cartilage,
while the sections incubated with the antibody alone
showed cartilage-specific staining (Fig. 1). Both sections
showed autofluorescence of the bone marrow, as has
previously been observed (upper left corner of both panels
in Fig. 1)27.
FLUORESCENCE MICROSCOPY
The stained sections were examined under an Olympus
BX51 fluorescence microscope for detection of degraded
type II collagen and photographed at 200× magnification
using a SPOT-RT Color digital camera (Diagnostic
Instruments Inc., Sterling Heights, Michigan). Measure-
ments of the area of degraded type II collagen staining
were taken from each quadrant of the joint – medial femur,
lateral femur, medial tibia, and lateral tibia. These four
measurements were summed to obtain the total area of
staining per joint. The individual quadrant measurements
were used for statistical analysis.
The area of staining representing denatured type II
collagen in the articular cartilage of each quadrant was
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measured using software calibrated to convert pixels to
area in square. Each quadrant was photographed at 200×
magnification and captured on the monitor, and the area of
staining was determined by outlining the exterior border of
the stained region as shown in Fig. 2. The SPOT-RT Color
software then converted the pixels contained in the
parameter drawn to square micrometers.
In addition to quantitative analysis of the stained area,
qualitative analysis was also performed. The knee joint
quadrants were examined visually for irregularities in the
ordinarily smooth border of the articular surface. This
analysis was done to detect any potential correlation be-
tween surface irregularities and the localized presence of
degraded type II collagen in the articular cartilage.
STATISTICAL ANALYSIS
A nonparametric analysis of variance (ANOVA) using
ranks of the ordered area-of-staining values was performed
on data from 12- and 15-month-old animals, in order to
determine whether the area of degraded type II collagen
staining in the experimental group differed significantly from
the control group. Using SAS software (SAS/STAT Version
8.2, 2001, SAS Institute Inc., Cary, NC, USA), each individ-
ual quadrant from each animal was given a rank based on
the area of staining. The ANOVA test used the variability
between animals to test the terms in the model, and not
the variability between individual quadrants from each
animal.
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Fig. 1. The COL2-3/4m antibody binds specifically to degraded type II collagen in cho/+ mice. Adjacent sections from a 15-month-old cho/+
mouse were stained either with normal COL2-3/4m antibody (A) or with COL2-3/4m antibody that had been preincubated with the peptide
CB11B, the epitope against which COL2-3/4m was generated (B). The blocking peptide completely prevented staining in the articular
cartilage, as expected. Note, however, that the underlying bone fluoresced even when the blocking peptide was used (top left of each panel).
This autofluorescence in the bone was present in all animals at all ages examined, as has been previously observed27.
Fig. 2. Illustration of the method by which area of staining was quantified. Using a SPOT-RT camera at a 200× magnification, a computer
mouse was used to trace the outline of the stained area of the articular cartilage (yellow outline). Calibrated software converted pixels to µm2,
and the area of staining was thereby quantified on one frame each from the lateral and medial femoral and tibial condyles of each animal.
Sections examined were from a depth between 750 and 900 µm beyond the posterior side of the patella. The section shown is from the
medial femur of a 15-month-old +/+ mouse.
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Results
6 AND 9 MONTHS
A thin layer of staining at the articular surface, too small
to measure, was observed in 50% of the 6- and 9-month-
old animals of both genotypes (data not shown). The other
50% of the animals showed no detectable staining in the
articular cartilage. The 6- and 9-month-old animals were
therefore not studied any further.
12 MONTHS
At 12 months, differences between +/+ and cho/+ be-
came apparent. One of the six control +/+ animals exam-
ined at 12 months had no detectable staining. The other
five showed staining at portions of the surface, with staining
in three of the animals extending 2–3 cell layers deep into
the articular cartilage (Fig. 3A). One animal exhibited two
surface irregularities, one in the lateral femur (not shown)
and one in the medial tibia (Fig. 4A). The average area of
staining measured per joint was 9 732 µm2 (Fig. 5A).
All of the 12-month-old cho/+ animals had detectable
staining, and five of the six had one or more localized
regions of staining that extended from the articular surface
2-3 cell layers deep into the articular cartilage. Three of the
six animals displayed 2–3 cell layers deep staining within
three of the four quadrants examined (Fig. 3C). One animal
had a surface irregularity in the medial tibia, which was also
the site of intense staining (Fig. 4C).
The average area of staining per joint measured in the
cho/+ mice was 17 374 µm2, 179% of the average area
measured in age-matched control animals (Fig. 5A). In
spite of this measurable difference in the mean area of
staining, the nonparametric statistical test showed that the
difference between +/+ and cho/+ was not statistically
significant with this sample size (P=0.07).
15 MONTHS
At 15 months of age, all of the +/+ mice showed staining
at the articular surface. In two of the five animals the
staining extended 2–3 cell layers deep in every quadrant
(Fig. 3B). A third animal contained deep staining in one
quadrant, the medial tibia. This staining was also the site
of a surface irregularity (Fig. 4B). The average area of
staining measured per joint was 12 881 µm2 (Fig. 5A).
In 15-month-old cho/+ mice, four of the five joints exam-
ined had regions of staining at least 2–3 cell layers deep on
all four quadrants examined (Fig. 3D). One animal showed
articular surface irregularities on both the lateral femur (not
shown) and the medial tibia (Fig. 4D), and both lesions
were accompanied by intense staining. Two other animals
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Fig. 3. Degraded type II collagen is detectable at the articular cartilage surface. Degraded collagen staining at the articular surface is visible
in representative sections of lateral femoral condyles from four mice representing the different ages and genotypes examined. Each section
is oriented with the femur entering the frame from above, and arrowheads indicate the cartilage surface.
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showed surface irregularities accompanied by intense
staining across the length of the lateral femur surface (not
shown).
The average area of staining measured per joint for the
15-month-old cho/+ animals was 23 877 µm2, 185% of the
average area measured in age-matched control animals
(Fig. 5A). The nonparametric statistical test demonstrated
that this difference was borderline significant (P=0.05) at
this sample size.
12 AND 15 MONTH POOLED
To increase sample size, 12-month-old and 15-month-old
animals were pooled and analyzed on the basis of geno-
type. The average area of staining measured per joint in the
pooled 12- and 15-month-old +/+ animals was 11 165 µm2
and in the pooled cho/+ animals was 20 330 µm2 (182% of
the area measured in the age-matched control animals)
(Fig. 5B).
The nonparametric statistical test performed on the
pooled samples revealed that the difference between area
of staining in +/+ and cho/+ animals was highly significant
(P=0.009).
Discussion
The cho mutation in the mouse Col11a1 gene has
historically been called recessive because it produces no
obvious phenotype when heterozygous. We show here,
however, that a disease phenotype is detectable in cho/+
mice. The 15-month-old C57BL mice that are heterozygous
for the cho mutation exhibit significantly more type II
collagen degradation than the +/+ C57BL mice that have
previously been shown to develop spontaneous OA detect-
able by histological analysis at around 15–17 months of
age28–30. The cho mutation appears to increase the rate of
collagen degradation once it begins, potentially resulting in
more rapidly advancing OA.
Several studies support the theory that type II collagen
degradation in the articular cartilage is associated with OA.
Mitchell et al. have shown that the collagenase MMP-13 is
expressed by chondrocytes in human OA cartilage20. Bank
et al. showed that decreased firmness and increased
swelling of the articular cartilage are strongly correlated
with the amount of degraded type II collagen present22.
Stoop and others have demonstrated type II collagen
degradation in both spontaneous and induced mouse and
rat models of OA17,18,21.
The strongest evidence that collagen degradation can
directly cause OA was produced by a study in which
Neuhold et al. selectively expressed the gene for MMP-13
in cartilage of transgenic mice26. The resulting mice
showed a striking increase in degraded type II collagen
around cells where MMP-13 was expressed. They also
showed focal lesions and severe erosions of the articular
cartilage, indicating that excessive MMP-13 activity had led
to OA.
Over expression of MMP-13 in transgenic mice directly
caused OA, but cho/+ mice differ in that the primary cause
of OA is the Col11a1 mutation. In some way the type XI
collagen mutation results in denaturation of type II collagen.
Fig. 4. Regions of surface irregularities and erosions often correspond with regions of intense staining for degraded type II collagen.
Representative sections of medial tibial condyles from four mice representing the different ages and genotypes examined are shown. Each
section is oriented with the tibia entering the frame from above. Arrows indicate surface irregularities and erosions.
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This could occur if the Col11a1 mutation produces articular
cartilage that is compromised in its structural integrity due
to a shortage of type XI collagen. The lack of structural
integrity might be severe enough to leave type II collagen
molecules vulnerable to biomechanical damage, resulting
in physical breakage and unwinding of the triple helix.
This explanation seems unlikely, however, given the
overtly normal development and apparent structural integ-
rity of cartilage in cho/+ mice during the first 12 months of
life. In the present study, very little denatured collagen
staining was detectable in the 6- or 9-month-old +/+ or
cho/+ mice examined. A difference in the amount of staining
between +/+ and cho/+ C57BL mice was detectable in
12-month-old animals but was not statistically significant.
By 15 months of age, however, cho/+ mice displayed
a modestly significant 1.9-fold more degraded collagen
staining than +/+ mice. Perhaps in the second year of life
the cumulative effects of mechanical strain on the joints of
both +/+ and cho/+ mice cause chondrocytes to upregulate
collagen synthesis and degradation to replace compro-
mised collagen fibrils with new fibrils. The early stages of
articular cartilage degeneration that eventually lead to OA
in +/+ C57BL mice may trigger a much more rapid cascade
of collagen degradation in cho/+ mice, due to the inability of
the cho/+ chondrocytes to produce adequate levels of type
XI collagen in the face of increasing collagenase activity.
This in turn could lead to regions of instability in the
cartilage extracellular matrix that appear as patches of
degraded and denatured collagen typical of OA. Colla-
genase activity, therefore, could greatly exacerbate the
effects of a minor structural weakness in the cartilage
collagen matrix and could explain the increased presence
of denatured type II collagen in mice containing a type XI
collagen mutation.
The results presented here support the hypothesis that
‘recessive’ collagen mutations in humans could also com-
promise the structural integrity of articular cartilage in
subtle ways, predisposing an individual to OA. Mechanical
strain or injury might trigger increased collagen synthesis
and degradation to replace damaged fibrils, but the genetic
inability to produce adequate amounts of any component of
the collagen matrix could lead to an imbalance between
synthesis and degradation. A relative increase in colla-
genase activity would predictably result in the abnormal
accumulation of degraded collagen with associated loss
of firmness and increase of swelling in the articular
cartilage22. Tissue erosion would likely follow.
The present study suggests that the cho/+ mouse is an
appropriate model in which to study genetically predis-
posed OA. Future studies will focus on the contribution of
collagenase activity to OA progression in this model and on
how factors such as activity level and mechanical strain
affect OA progression when a genetic predisposing factor is
present.
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